Basildon, UK, January 31 2016 – Atnahs Pharma US Limited (“Atnahs”) is pleased to announce the acquisition of Naproxen Suspension from Pediapharm Inc. in a total transaction of US$4.25 million.
The product is currently awaiting Food and Drug Administration (“FDA”) Supplement Approval regarding the manufacturing site transfer.
Atnahs Press Contact
Dr Amit Patel
Phone: +44 1268 943 700